|

KRT-232 Clinical Trials

1 actively recruiting trial across 1 location

No change since June 2026

Pipeline

Phase 1/2: 1

Top Sponsors

  • Kartos Therapeutics, Inc.1

Indications

  • Chronic Lymphocytic Leukemia1
  • Non-hodgkin Lymphoma1
  • Diffuse Large B-Cell Lymphoma1
  • Cancer1

Goshen, Indiana1 trial

Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL

Goshen Center for Cancer Care

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.